A Phase 1, Multi-center, Open-label, Uncontrolled, Dose-escalation Trial to Evaluate the Safety of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Latest Information Update: 17 Feb 2025
At a glance
- Drugs Bendamustine (Primary) ; OPB 111077 (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical
Most Recent Events
- 30 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2023 Results (n=16) showing preliminary data of efficacy of OPB-111077 combination treatment in patients with DLBCL presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 06 Dec 2023 Planned End Date changed from 1 May 2023 to 1 Mar 2025.